For patients with nAMD who are developing GA in the same eye, do you consider adding anti-complement therapy?  

My personal perspective, shared by many colleagues around the country, is that the minimal anatomic and functional benefit of anti-complement therapy does not outweigh the aggregate risks and costs of perpetual treatment with these agents. I discuss these issues with my GA patients (including those ...

There is no data on this as patients with pre-existing nAMD were not included in the trials. I will consider treating such patients, but only after discussing the data in detail and the lack of clarity on this specific question.